New mRNA Vaccine Reduces Risk of Melanoma Recurrence by Over 40 Percent
24 octobre 2026 | Fernanda González
The vaccine is personalized to a patient’s tumor, and results from the Phase 3 trial are yet another example of the promise of mRNA vaccines in treating cancer.
